Mobilization of peripheral blood stem cells using regimen combining docetaxel with granulocyte colony-stimulating factor in breast cancer patients

Chinese Journal of Cancer Research

Volumn 23, Issue 1, 2011, Pages 49-53

  Yu, Jing ^a   Ren, Jun ^a   Di, Li Jun ^a   Song, Guo Hong ^a   Zhu, Yu Lin ^a   Zhang, Jie ^a   Liang, Xu ^a   Che, Li ^a   Jiang, Han Fang ^a   Jia, Jun ^a   Zhang, Chun Rong ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Docetaxel; Granulocyte colony stimulating factor (G CSF); Mobilization; Stem cell

Indexed keywords

CD34 ANTIGEN; DEXAMETHASONE; DOCETAXEL; GLUCONATE CALCIUM; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL ISOLATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLOW CYTOMETRY; FOOT PARESTHESIA; HAND PARESTHESIA; HEMATOPOIETIC STEM CELL; HUMAN; LEUKAPHERESIS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MOUTH DISEASE; PARESTHESIA; PERIORAL NUMBNESS; PERIPHERAL BLOOD MONONUCLEAR CELL; SIDE EFFECT; STEM CELL MOBILIZATION; THROMBOSIS; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 79953192532     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.1007/s11670-011-0049-8     Document Type: Article

References (22)

1. Gluz O, Nitz UA, Harbeck N, et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol 2008; 19:861-70. (Pubitemid 351649186)
2. Zander AR, Schmoor C, Kröger N, et al. Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up. Ann Oncol 2008; 19:1082-9. (Pubitemid 351796333)
3. Nitz UA, Mohrmann S, Fischer J, et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 2005; 366:1935-44.
4. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21:1431-9. (Pubitemid 46594092)
5. Stadtmauer EA, Schneider CJ, Silberstein LE. Peripheral blood progenitor cell generation and harvesting. Semin Oncol 1995; 22: 291-300.
6. Gómez-Espuch J, Moraleda JM, Ortuño F, et al. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotherapeutic agent, associated with rhG-CSF. Bone Marrow Transplant 2000; 25:231-5. (Pubitemid 30103010)
7. Weaver CH, Schwartzberg LS, Birch R, et al. Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer. Biol Blood Marrow Transplant 1997; 3:83-90. (Pubitemid 127529981)
8. Burris HA 3rd. Single-agent docetaxel (Taxotere) in randomized phase III trials. Semin Oncol 1999; 26:1-6.
9. Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18:1212-9. (Pubitemid 30159838)
10. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracyclinepretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812-23. (Pubitemid 34651510)
11. Gorin NC. Collection, manipulation and freezing of haemopoietic stem cells. Clin Haematol 1986; 15:19-48. (Pubitemid 16144372)
12. Ikeda K, Kozuka T, Harada M. Factors for PBPC collection efficiency and collection predictors. Transfus Apher Sci 2004; 31:245-59. (Pubitemid 39535521)
13. DeLuca E, Sheridan WP, Watson D, et al. Prior chemotherapy does not prevent effective mobilisation by G-CSF of peripheral blood progenitor cells. Br J Cancer 1992; 66:893-9.
14. Teshima T, Harada M, Takamatsu Y, et al. Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting. Bone Marrow Transplant 1992; 10:215-20.
15. Imamura R, Miyamoto T, Yoshimoto G, et al. Mobilization of human lymphoid progenitors after treatment with granulocyte colony-stimulating factor. J Immunol 2005; 175:2647-54. (Pubitemid 41113880)
16. Dührsen U, Villeval JL, Boyd J, et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72:2074-81. (Pubitemid 19030905)
17. To LB, Haylock DN, Simmons PJ, et al. The biology and clinical uses of blood stem cells. Blood 1997; 89:2233-58. (Pubitemid 27143269)
18. Burtness BA, Psyrri A, Rose M, et al. A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells. Bone Marrow Transplant 1999; 23:311-5. (Pubitemid 29105953)
19. Baur M, van Oosterom AT, Diéras V, et al. A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer. J Cancer Res Clin Oncol, 2008, 134:125-35. (Pubitemid 350234056)
20. Prince HM, Toner GC, Seymour JF, et al. Docetaxel effectively mobilizes peripheral blood CD34+ cells. Bone Marrow Tansplant 2000; 26: 483-7.
21. Laport GG, Fleming GF, Waggoner S, et al. A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer. Bone Marrow Transplant 2001; 27: 677-81. (Pubitemid 32409440)
22. Fleming DR, Goldsmith J, Goldsmith GH, et al. Mobilization of peripheral blood stem cells in high-risk breast cancer patients using G-CSF after standard dose docetaxel. J Hematother Stem Cell Res 2000; 9:855-60. (Pubitemid 32110284)